Introduction
Human cancer risk assessment is conventionally based on estimates of administered dose and/or human exposure, i.e., the amount of carcinogen in the external environment. Of far greater relevance to risk is the biologically effective dose or the actual amount of carcinogen that has interacted with critical cellular targets such as DNA, RNA, or protein (1, 2) . This paper will summarize progress to date in quantifying biologically effective dose of carcinogens in humans-in particular, DNA and protein adducts-in order to address the question, "How can these biological markers improve quantitative risk assessment?" Available markers of biologically effective dose include DNA adducts, protein adducts as a surrogate, cytogenetic effects [e.g., chromosomal aberrations (CA), sister chromatid exchange (SCE), and micronuclei (MN)], DNA damage and repair [e.g., unscheduled DNA synthesis (UDS)], and somatic cell mutation [e.g., hypoxanthine(guanine)phosphoribosyltransferase (HPRT) and glycophorin A] (2-4). All are relevant to the multistage process of chemical carcinogenesis, which is believed to involve genetic damage at one or more stages (5) (6) (7) . Each of these methods has been applied in at least two human study populations (2, 8) . (Table 1 ). Significant increases in levels of each of these biological markers have generally been observed in exposed individuals compared to baseline or control values.
There is general agreement that these biomarkers can A growing body of data regarding DNA and protein adducts in human populations with quantifiable exposures to diverse carcinogens illustrates two important points relevant to quantitative risk assessment (Tables  2 and 3) . First, there is significant interindividual variation in binding levels, even when external exposure is comparable. For example, levels of benzo[a]pyrene-DNA (BP-DNA) in smokers of 1 to 2 ppd ranged from nondetectable (ND) to 0.21 fmole adducts/,ug DNA, and 4-aminobiphenyl-hemoglobin (4-ABP-Hb) concentrations ranged from 0.44 to 1.5 pmole/g (11) . In cisplatinum-treated cancer patients, adduct levels ranged from ND to 0.4 fmole/,g (15) . Significant levels of cisplatinum-DNA (cis-DPP-DNA) adducts occurred in only about 50% of subjects receiving standardized doses of chemotherapy while the other half sustained no measurable biological dose (15) .
Second, there is a significant background in so-called "unexposed" controls, e.g., in worker controls and nonsmokers. In all of the studies summarized in Table 2 , the mean values for controls were significantly greater than zero. In all cases there was overlap in DNA adduct levels between exposed and control groups. This is not unexpected given the multiple sources of environmental carcinogens including passive smoking, the food supply, ambient air, etc.
Regarding the low dose-response curve (i.e., exposure-adduct curve) in humans, data are limited, but for reasons just discussed do not indicate a threshold for adduct formation by polycylic aromatic hydrocarbons (PAH), 4-aminobiphenyl (4-ABP), ethylene oxide (EtO), and tobacco smoke constituents. A reasonably linear relationhip was seen between estimated EtO exposure and EtO protein in a small number of sterilization plant workers (17) . Similarly, the cumulative dose of cisplatinum was linearily related to levels of cisplatinum-DNA adducts in the individuals who formed measurable adducts (15) .
A recent study of DNA adducts in Finnish iron foundry workers (n = 35) indicates a dose-response for benzo[a]pyrene-DNA (BP-DNA) by immunoassay and a significant increase in adduct levels in exposed individuals compared to controls (12) . Foundry workers have an increased risk of lung cancer, with highest risk seen for casters (19 Regarding the first question, the convention as reaffirmed in the EPA Guidelines on Assessment of Cancer Risk (20) is to use a multistage model that assumes additivity on background and hence is linear at low dose. This model is widely considered to be the most biologically plausible of available models, but there are many uncertainties as to the true dose-response relationship, even in the experimental animal.
There have been a number of attempts to test whether low-dose linearity is a valid assumption by comparing administered dose to macromolecular binding in laboratory animals (Table 4 ). The first set of studies in Table 4 gave a single dose (or in one case a repeat dose), often over a wide range (in one instance 4-5 orders of magnitude). Generally, exposures were considerably higher than those encountered by humans, with the exception of benzo[a]pyrene (29) . The compounds listed gave a constant ratio between administered dose and binding to DNA and/or protein. In the case of formaldehyde, however, a nonlinear dose-response for putative formaldehyde-DNA-protein cross-links was seen in rats exposed by inhalation during two 6-hr periods (30) .
Chronic or multiple dose studies have, with few exceptions, shown a constant ratio between administered dose and DNA or protein adducts (Table 4 ). In addition to low-dose linearity, a plateau in DNA adduct formation was generally observed at higher doses of the carcinogens in Table 4 . Only dimethylnitrosamine (DMN) gave a nonlinear dose response regarding protein adduct formation (23 One well-developed effort to utilize laboratory and human biomonitoring adduct data to predict risk is that of Ehrenberg et al. for EtO (40) . Here macromolecular (hemoglobin) binding was experimentally determined to be directly proportional to target tissue dose. Relationships between tissue dose, target, and molecular dose were experimentally determined, as was the tissue dose of EtO that would produce the same number of mutations as a unit of radiation (or the radiation equivalent dose of EtO). EtO-histidine adducts were measured in sterilization plant workers, and the risk of a 1 ppm-hr of EtO exposure was estimated to be equivalent to 10 mrad of radiation (17) . The workers' average tissue dose of EtO was converted to radiation risk equivalents. Excess cancer risk (leukemia) was predicted, which is similar to that seen in follow-up epidemiological studies of that cohort (41) . EtO may be a special case in that it is a direct-acting and stable electrophile that distributes uniformly in different tissues.
In summary, this is a challenging and exciting time for both DNA adduct research and risk assessment. To fulfill the promise of a partnership between the two disciplines, we clearly need more parallel chronic exposure data on binding in experimental models and humans as well as prospective studies in animals and model human populations exposed to the same environmental carcinogens.
